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Abstract: Elucidating the underlying cause of unexplained syncope, palpitations or other possible arrhythmia-related 
symptoms is a formidable clinical challenge. Cardiac monitoring supplements the most important “test” in patients with 
syncope or palpitations, that of a thoughtful history and physical examination. Ideally, comprehensive physiologic moni-
toring during spontaneous symptoms would constitute what, at present, is an unattainable gold standard test for establish-
ing a cause. Short of that goal, establishing an accurate symptom-rhythm correlation can often provide a diagnosis. Ambu-
latory outpatient monitoring is a powerful diagnostic tool for the evaluation of cardiac arrhythmias. Evolving technologies 
have provided a vast array of monitoring options for patients suspected of having cardiac arrhythmias, with each modality 
differing in duration of monitoring, quality of recording, convenience and invasiveness. Holter monitors, event monitors 
and external loop recorders are non-invasive and provide easily accessible short-term monitoring solutions. In instances 
where the diagnosis remains elusive, a more long-term strategy with an implantable loop recorder may be the preferred 
path. 
INTRODUCTION 
  The term syncope has its origins in ancient Greek. From 
anetymologicalviewpoint,itis composed of the prefix “syn”, 
meaning with or together, and the verb “copto”, meaning to 
cut short or interrupt. The sine qua non of syncope is tran-
sient loss of both consciousness and voluntary muscle tone 
secondary to a temporary global reduction in cerebral blood 
flow. Syncope is a frequently encountered clinical conun-
drum with an estimated lifetime prevalence of up to 35% [1]. 
Syncope accounts for up to 3% of emergency department 
consultations and 6% of hospital admissions [2-4]. Elucidat-
ing the underlying cause of unexplained syncope can pose a 
clinical challenge, which is difficult yet worthwhile, as iden-
tification of underlying cardiac disease in patients with syn-
cope is associated with higher rates of mortality and morbid-
ity [5]. Although the most important “test” in patients with 
syncopeorpalpitations remains a thorough history and physi-
cal examination [6,7], cardiac monitoring is an essential di-
agnostic adjunct. Choice of investigative modalities is de-
termined by the initial clinical evaluation. For instance, pa-
tients presenting with exercise-induced syncope benefit from 
cardiac imaging to exclude structural disease such as a hy-
pertrophic cardiomyopathy or coronary artery disease [8]. 
Further investigation with exercise stress testing can lead to 
the diagnosis of ischemia or arrhythmias precipitated by ex-
ercise, in contrast to post-exertional syncope that may be 
associated with autonomic dysfunction [2]. Comprehensive 
physiologic monitoring during spontaneous symptoms con-
stitutes an often unattainable gold standard for establishing a 
cause. Short of that goal, establishing an accurate symptom-
rhythm correlation can often provide a diagnosis, making 
ambulatory outpatient monitoring a powerful diagnostic tool 
for the evaluation of cardiac arrhythmias. Evolving tech-
nologies have provided a wide array of monitoring options  
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for patients suspected of having cardiac arrhythmias, with 
each modality differing in duration of monitoring, quality of 
recording, convenience, and invasiveness. Holter monitors, 
event monitors and external loop recorders are non-invasive 
and provide easily accessible short-term monitoring. In in-
stances where the diagnosis remains elusive, a longer-term 
strategy with an implantable loop recorder (ILR) may be the 
preferred path.  
HOLTER MONITORING 
  A standard ECG should be ordered for all patients with 
syncope [2,9]. Short term electrocardiographic monitoring 
via three or, in some cases, twelve surface electrodes is the 
most common initial investigation in patients who present 
with syncope or palpitations. Typically this occurs in the 
emergency room or primary care setting with telemetry and 
continuous monitoring. More recently, however, wireless 
telemetry offers the possibility of reviewing continuous elec-
trocardiogram recordings instantaneously at particular access 
points [10]. Nonetheless, the overall diagnostic yield of Hol-
ter monitoring is low. In a pooled analysis by Linzer et al., 
among patients with symptoms of syncope or presyncope 
there was a 4% correlation between symptoms and arrhyth-
mias with Holter monitoring for more than 12 hours [9].  
  The findings on electrocardiographic monitoring must be 
correlated with symptoms, as heart rate, and even cardiac 
rhythm, is often uninformative in the absence of clinical cor-
relation. The major limiting factor in the diagnosis of the 
index event is the likelihood of another syncopal episode 
during the monitoring period. Holter monitoring can also be 
used as a strategy to exclude a significant arrhythmic cause 
of symptoms in the primary care setting. Presyncope is a 
more common event during ambulatory monitoring but is 
less likely to be associated with an arrhythmia [11,12]. Addi-
tionally, the ubiquitous nature of presyncope makes it a rela-
tively poor surrogate for the assessment of syncope.  
  Holter monitoring is useful in unexplained syncope or 
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patient at relatively high risk for arrhythmia (i.e. underlying 
structural heart disease or abnormal baseline electrocardio-
gram). The Holter monitor is a portable battery-operated 
device that connects to the patient using electrodes, provid-
ing recordings from up to twelve electrocardiographic leads. 
Data are stored in the device using analog or digital storage 
media. The data are transformed into a digital format and 
analyzed using interpretive software. Additional markers for 
patient-activated events and time correlates are included, 
along with a patient event diary, to allow greater diagnostic 
accuracy. Continuous electrocardiographic monitoring is 
possible for a maximum of 48 hours (See Fig. 1). This may 
allow the documentation of cardiac rhythm during sympto-
matic and/or asymptomatic events.  
Fig. (1). Holter Monitor. 
The recording device is worn by the patient using a shoulder strap 
or belt loop, attaching to 3-5 skin electrodes for continuous moni-
toring. An event button (not shown) at the top of the housing of the 
device is pressed in the event of symptoms to mark the recording. 
See text for discussion.
  There are, however, a number of limitations with Holter 
monitoring. The major limitation is that patients may not 
experience symptoms or cardiac arrhythmias during the re-
cording period. The physical size of the device may impair 
the ability of patients to sleep comfortably or engage in ac-
tivities that precipitate or reproduce symptoms. Patients are 
further inconvenienced because the device has to be removed 
while showering or bathing. There is also considerable vari-
ability in patient documentation and recollection of activated 
events, such that accurate symptom-rhythm correlation is 
undermined. It is therefore not surprising that Holter moni-
toring has a low diagnostic yield. In several large series of 
patients undergoing twelve or more hours of ambulatory 
monitoring for investigation of syncope, only 4% had recur-
rence of symptoms during monitoring [9,13,14]. The overall 
diagnostic yield of ambulatory or Holter monitoring was 
19%. Uncommon asymptomatic arrhythmias such as pro-
longed sinus pauses, atrio-ventricular block (such as Mobitz 
type II block), and non-sustained ventricular tachycardia can 
provide important contributions to the diagnosis, often ne-
cessitating further investigations to rule out structural heart 
disease and other precipitating factors. While these observa-
tions require prompt attention, it is important to interpret the 
results in the clinical context of the syncopal presentation so 
that common causes of syncope, such as neurocardiogenic 
syncope, are not unduly excluded.  
  It is also important to recognize that normal ambulatory 
electrocardiographic monitoring does not exclude an ar-
rhythmic cause for syncope. If the pre-test probability is high 
for an arrhythmic cause, then further investigations such as 
prolonged monitoring or electrophysiological studies are 
required. One study has investigated an extended duration of 
ambulatory Holter monitoring of 72 hours [13]. In this study, 
an increased number of asymptomatic arrhythmias were de-
tected, even though the overall diagnostic yield was not im-
proved. The more frequent the symptoms, the higher the 
diagnostic yield of Holter monitoring. The apparent modest 
yield of Holter monitoring presumably reflects the primary 
care use of the device in patients with frequent symptoms, 
facilitating a symptom-rhythm correlation. This leads to se-
lection bias in the referral population, as referred patients 
tend to have failed short term monitoring, suggesting infre-
quent symptoms and the need for longer-term monitoring 
strategies. 
EXTERNAL LOOP RECORDERS AND TRANSTELE-
PHONIC MONITORS  
  Transtelephonic electrocardiographic monitors are re-
cording devices that transmit data via an analog phone line to 
a base station (Fig. 2). The signal is then converted to an 
interpretable recording that is displayed or printed as a single 
lead rhythm strip. There are two specific types of devices. 
Fig. (2). Transtelephonic Monitors. 
The device is lightweight and portable. Four recording electrodes 
are present on the back of the device to permit single lead rhythm 
strip capture. A record button (top left) is pressed at the onset of 
symptoms, and the recorded event is transmitted to a base station 
over an analog phone line. Syncope: Review of Monitoring Modalities  Current Cardiology Reviews, 2008, Vol. 4, No. 1    43
The first does not save a recording of the rhythm for later 
playback and requires the patient to transmit the data to the 
base station, where it can be analyzed. The second type of 
device, with solid-state memory capacity allowing recording 
and storage of electrocardiographic signals during symp-
toms, has replaced the non-recording units. The electrocar-
diographic signals are collected on a real-time minute loop.  
  An external cardiac loop recorder continuously records 
and stores an external single modified limb lead electrogram 
with a 4-18 minute memory buffer (Fig. 3, left). After the 
onset of spontaneous symptoms the patient activates the de-
vice, which stores the previous 3-14 minutes, and the follow-
ing 1-4 minutes, of recorded information. The captured 
rhythm strip can subsequently be uploaded and analyzed 
(Fig. 4) and often provides critical information regarding the 
onset of the arrhythmia. This system can be used for weeks 
to months provided weekly battery changes are performed. 
The recording device is attached with two leads to the pa-
tient’s chest wall and needs to be removed for bathing or 
showering, and can be uncomfortable during sleep.  
Fig. (3). Loop Recorders. 
An external loop recorder (left) with cables that attach to the pa-
tient. The record button is pressed in the event of symptoms to store 
the previous 9 minutes, and the ensuing minute. The phone receiver 
is also placed over this button to transmit data over an analog phone 
line. An implantable loop recorder (center) and patient activator 
(right). The patient activator is used to “freeze” symptomatic events 
that are retrieved with a pacemaker programmer. Automatic events 
can also be captured (see text for discussion).
  Long-term compliance with this device can be challeng-
ing because of electrode and skin-related problems and wan-
ing of patient motivation in the absence of recurrent symp-
toms. Linzer et al. reported the use of patient-activated loop 
recorders in 57 patients with syncope and non-diagnostic 
findings on history, physical examination and 24 hour Holter 
monitoring [15,16]. A diagnosis was obtained in 14 of 32 
patients who had recurrence of symptoms. Device malfunc-
tion, patient non-compliance or inability to activate the re-
corder was responsible for the lack of diagnosis in the re-
maining 18. Other studies have also reported similar findings 
[16,17] and demonstrated that loop recorders are comple-
mentary to 24 hour ambulatory electrocardiographic moni-
toring. The diagnostic yield for external loop recorders in 
these three studies [15-17] ranged from 24%-47%, with 
highest yield in patients with palpitations. 
  A prospective randomized clinical trial compared the 
utilityofexternalloop recorders to conventional Holter moni-
toring in a community based referral population with syn-
cope and presyncope [18]. Not surprisingly, the ability to 
obtain a symptom-rhythm correlation was 22% for Holter 
monitoring and 56% for the external loop recorder (p < 
0.001), with a duration of monitoring of 48 hours and 4 
weeks, respectively. A higher diagnostic yield was also ob-
tained among patients randomized to Holter monitoring who 
remained undiagnosed and crossed-over to use of a loop re-
corder. This trial suggests that loop recorders should be con-
sidered as first line monitoring when attempting to establish 
a symptom rhythm correlation in the initial workup of pa-
tients with syncope. Twenty-four percent of loop recorder 
patients failed to activate the device properly, suggesting 
limited usefulness in some patients [18]. Analysis of factors 
pertaining to use of external loop recorders has revealed a 
particularly low diagnostic yield among patients who are 
unfamiliar with technology, live alone, or have low motiva-
tion for achieving a diagnosis [19]. Reiffel et al. [20] retro-
spectively compared the results obtained by Holter monitor-
ing, loop recording and auto-triggered loop recording in 600 
patients from a database of approximately 100,000 patients. 
The auto-triggered loop recording approach provided a 
higher yield of diagnostic events (36%) compared to loop 
recording (17%) and Holter monitoring (6.2%).  
  The external loop recorder appears to have its greatest 
role in motivated patients with frequent spontaneous symp-
toms that are likely to recur within 4-6 weeks. Given that it is 
non-invasive and cost effective, loop recording should be 
considered in all patients in whom an arrhythmic cause for 
syncope is suspected, keeping in mind that the major limita-
tion of this device is the need to continuously wear external 
electrodes.  
IMPLANTABLE LOOP RECORDERS 
  The implantable loop recorder (ILR) is a relatively recent 
investigational tool in undiagnosed syncope that permits 
prolonged monitoringwithoutexternal electrodes. It is ideally 
suited to patients with infrequent recurrent syncope thought 
to be due to an arrhythmic cause. Similar to the external loop 
recorder, it is designed to correlate physiology with recorded 
cardiac rhythms, but implanted and therefore devoid of sur-
face electrodes and accompanying compliance issues. The 
ILR also monitors much longer time periods than an external 
loop recorder. Currently the only FDA approved ILR (Med-
tronic Reveal Plus
® Model 9526) has a pair of sensing elec-
trodes with 3.7 cm spacing on a small elongated recording 
device 6 cm long, 2 cm wide 0.8 cm thick, and weighing 17 
grams (Fig. 3, center). The battery life is 18-24 months. The 
device can be implanted subcutaneously in the chest wall 
under local anesthetic and with antibiotic prophylaxis.  
  Prior to implantation, cutaneous mapping should be per-
formed to optimize the sensed signal and avoid T-wave over-
sensing, which can be falsely interpreted as a high rate epi-
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in the left hemithorax [21]. The recorded bipolar signal is 
stored in the device as 21 minutes of uncompressed or 42 
minutes of compressed signal. A compressed signal is gener-
ally used with only marginal loss of quality while maximiz-
ing memory capability. The patient, along with a spouse, 
family member or friend is instructed in the use of the activa-
tor at the time of implant. Once an episode is recorded (i.e. a 
presyncopal or syncopal event occurs) the memory is “fro-
zen” by the patient or a relative using a non-magnetic hand 
held activator (Fig. 3, right). The episode is then uploaded 
for interrogation to a pacemaker programmer (Medtronic 
9790, Medtronic, Minneapolis, Minnesota, U.S.). Although 
heart rate is usually easily ascertained, p waves can occa-
sionally be challenging to interpret. The current version of 
the ILR has programmable automatic detection of rapid and 
slow heart rate episodes as well as pauses.  
  A classification system for recorded events has been pro-
posed by Brignole et al. [22] (Table 1) that categorizes the 
probable mechanism of syncope according to the pattern of 
bradycardia recorded during spontaneous episodes. An ex-
ample of the cardioinhibitory component of neurocardio-
genicorvasovagalsyncope is illustrated in Fig. 5. This would 
be considered a 1A response. Fig. 6 illustrates a primary 
bradycardia (1C response), highly suggestive of intrinsic AV 
node disease. This classification is useful for research pur-
poses for event classification, and is likely to prove useful in 
directing therapy once validated. 
  Currently there are several studies establishing the utility 
of ILR in the diagnosis of syncope [22-27]. One of these 
studies is a multi-centre study of 206 patients [26]. The ma-
jority of patients had undergone non-invasive and invasive 
testing including head-up tilt testing and electrophysiological 
studies. The etiology of syncope was arrhythmic in 22% of 
patients. Fourty-two percent had further symptoms with only 
sinus rhythm documented, and 22% had no further episodes 
[26]. Bradycardia was the most commonly detected arrhyth-
mia (17% vs. 6% tachycardia), usually leading to pacemaker 
implantation [26]. From this study, 4% of patients failed to 
properly activate the device and thus did not establish a 
symptom rhythm correlation. The devices used in this study 
did not contain the automatic detection feature. Multivariate 
modeling did not identify any significant pre-implant predic-
tors of subsequent arrhythmia detection other than a weak 
associationwithadvancingageandbradycardia. No age group 
had an incidence of bradycardia greater than 30% [26]. 
  In a group of patients with ongoing seizures despite anti-
convulsant therapy, Zaidi et al. performed cardiac assess-
ment including head-up tilt testing and carotid sinus massage 
in all patients, and implantation of an ILR in ten patients 
[28,29]. Two of the ten patients with an ILR had marked 
bradycardia preceding a seizure; one due to sinus pauses and 
the other due to heart block. Importantly, this study sug-
gested seizures that are atypical in presentation may have a 
cardiovascular cause in as many as 42% of cases, and car-
Fig. (4). External Loop Recorder Tracing. 
Sinus rhythm during presyncope is recorded in a 43-year-old female with recurrent unexplained syncope and presyncope. The fluctuation in 
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diovascular assessment including long term cardiac monitor-
ing with an ILR may play a role in select patients with atypi-
cal seizures.  
  In three studies [2,30,31] from the International Study on 
Syncope of Uncertain Etiology (ISSUE) investigators, ILRs 
were implanted in different groups of patients with syncope 
to assess cardiac rhythm during episodes, after conventional 
testing. The first study involved tilt tests in 111 patients with 
unexplained syncope, and loop recorders implanted after the 
tilt test, regardless of result [30]. Syncope recurred in 34% of 
patients in both the tilt positive and tilt negative group, with 
marked bradycardia or asystole the most commonly recorded 
arrhythmia during follow-up (46% and 62% respectively). 
The heart rate during tilt testing did not predict spontaneous 
heart rate response, with a much higher incidence of asystole 
than expected based on demographics or tilt. This study sug-
gests that observations during tilt testing correlate poorly 
with cardiac rhythm during spontaneous syncope, and that 
bradycardia is more common in this population than previ-
ously recognized. This was observed in ISSUE 2, where ap-
proximately 12% (47/392 patients) had asystole documented 
as the cause of recurrent syncope [32]. An ILR study of 
symptomatic vasovagal patients also showed that the heart 
rhythm observed during a spontaneous syncope did not cor-
relate with the head-up tilt test [33]. An example of the car-
dioinhibitory component of vasodepressor syncope is illus-
trated in Fig. 5.
  In the second study, 52 patients with syncope, bundle 
branch block and negative electrophysiologic testing under-
went ILR implantation [2]. Syncope recurred in 22 of the 52 
patients with conduction system disease. Long term monitor-
ing demonstrated marked bradycardia mainly attributed to 
complete AV block in 17, while it excluded AV block in 2. 
Three patients did not properly activate the device after 
symptoms. This study confirmed that negative electrophysi-
ologic testing does not exclude intermittent complete AV 
block, and that prolonged monitoring or consideration of 
permanent pacing is reasonable in this population. 
  The third study examined the spontaneous rhythm in 35 
patients with syncope, overt heart disease and negative elec-
trophysiologic testing [31]. The underlying heart disease was 
predominantly ischemic or hypertrophic cardiomyopathy 
with moderate left ventricular dysfunction. Although previ-
Table 1.  ISSUE Classification of Detected Rhythm from the ILR 
Classification  Sinus Rate  AV Node  Comment  Presumed Mechansim 
Asystole (RR>3 sec) 
1A Arrest  Normal  Progressive sinus bradycardia with sinus
arrest:  
vasovagal 
1B Bradycardia  AV  block  AV block with associated sinus brady-
cardia:  
vasovagal 
1C  Normal or tachycar-
dia 
AV block  Abrupt AV block without sinus slowing  intrinsic AV node disease 
Bradycardia 
2A Decrease>30%  Normal    vasovagal 
2B  HR<40 for >10 sec-
onds 
Normal   vasovagal 
Minimal HR change 
3A  <10% variation  Normal  Suggests unlikely vasovagal  non-cardiac cause 
3B  HR increase or de-
crease 10-30%, not 
<40 or >120 bpm 
Normal   vasovagal 
Tachycardia 
4A  Progressive tachycar-
dia 
Normal  Sinus acceleration typical  orthostatic intolerance or non-
cardiac cause 
4B N/A  Normal  Atrial  fibrillation 
4C N/A  Normal  Supraventricular  tachycardia 
4D N/A  Normal  Ventricular  tachycardia 
Mixed – may be a component of 
vasovagal as well 
HR – heart rate, N/A – not applicable 
Adapted from Brignole M, Moya A, Menozzi C, Garcia-Civera R, Sutton R. Proposed electrocardiographic classification of spontaneous syncope documented by an implantable loop 
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ous studies have suggested that patients with negative elec-
trophysiologic testing have a better prognosis, there remains 
concern regarding risk of ventricular tachycardia in this 
group. Symptoms recurred in 19 of the 35 patients (54%), 
with bradycardia in 4, supraventricular tachyarrhythmias in 5 
and ventricular tachycardia in only 1 patient. There were no 
sudden deaths during 16 ±11 months of follow-up. 
  A prospective randomized trial compared early use of the 
ILR for prolonged monitoring to conventional testing in pa-
tients undergoing a cardiac workup for unexplained syncope 
(Randomized Assessment of Syncope Trial – RAST) [24, 
34]. Sixty patients (age 66 ±14 years) with unexplained syn-
cope were randomized to “conventional” testing with an ex-
ternal loop recorder, tilt test and electrophysiologic study 
versus one year of monitoring with an implantable loop re-
corder. Patients were excluded if they had a left ventricular 
ejection fraction less than 35%. If patients remained undiag-
nosed after their assigned strategy, they were offered cross-
over. A diagnosis was obtained in 14 of 27 patients random-
ized to prolonged monitoring, compared to 6 of 30 undergo-
ing conventional testing (52% vs. 20%, p=0.012). Overall, 
prolonged monitoring was more likely to result in a diagno-
sis than conventional testing (55% vs. 19%, p=0.0014). 
Bradycardia was detected in 14 patients undergoing monitor-
ing, compared to 3 patients with conventional testing (40% 
vs. 8%, p=0.005). These data highlight the diverse etiology 
of syncope, and also illustrate the limitations of conventional 
diagnostic techniques. Although there is clear selection bias 
Fig. (6). Manual Event Detection from an ILR. 
Manual activation during presyncope in a 73-year-old male with two previous episodes of unexplained syncope. There is subsequent sinus 
showing suggests a secondary vasovagal response.This is classified as a 1C response by the proposed ISSUE classification, suggesting in-
trinsic AV node disease.  
Fig. (5). Automatic Event Detection from an ILR. 
This is a typical tracing of an event captured by an ILR during syncope in a patient. The arrow and letter A denotes automatic activation 
when the device detects a 3 second pause. Each line constitutes 10 seconds of a single lead rhythm strip. Note the slowing of the sinus rate 
prior to onset of a prolonged pause, which resulted in syncope. This is consistent with the diagnosis of neurocardiogenic syncope (ISSUE 
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in enrollment of patients referred to an electrophysiologist 
for workup, this study suggests that tilt testing has a modest 
yield when applied to all patients undergoing investigation 
for unexplained syncope, and that electrophysiologic testing 
is of very limited utility in patients with preserved left ven-
tricular function. Also in patients with a negative electro-
physiology study for suspected arrhythmia tilt testing has 
been shown to be of little value in predicting the mechanism 
of syncope [35].
  A recent prospective, multicenter observational study 
(ISSUE 2) investigated the efficacy of therapies based on 
ILR diagnosis of recurrent suspected neurocardiogenic syn-
cope [32]. Patients were included in the study if they experi-
enced three or more clinically severe syncopal episodes over 
2 years without significant electrocardiographic or cardiac 
abnormalities. Those with postural hypotension and carotid 
sinus syncope were excluded. After the first documented 
episode of syncope after ILR implantation, the device was 
interrogated and therapy was prescribed accordingly. The 1-
year recurrence rate of syncope in 392 patients was 33%. 
Among 103 patients with a documented episode, 53 patients 
received loop recorder directed therapy; 47 receiving a pace-
maker due to asystole and 6 receiving anti-tachyarrhythmia 
therapy (catheter ablation: four, implantable defibrillator: 
one, anti-arrhythmic drug: one). The remaining 50 patients 
did not receive specific therapy. The 1-year recurrence rate 
among the 53 patients assigned to a specific therapy was 
10% compared with 41% in the patients without specific 
therapy. The 1-year recurrence rate in patients with pace-
makers was 5%. The authors concluded that a strategy based 
on diagnostic information from early ILR implant, with ther-
apy delayed until documentation of syncope, allows safe, 
specific, and effective therapy in patients with neurocardio-
genic syncope. 
STRATEGIES FOR CHOOSING PROLONGED MONI-
TORING 
  The literature clearly supports the use of the implantable 
loop recorder in patients with recurrent unexplained syncope 
that have failed a non-invasive workup and continue to have 
episodes. This represents a select group that has been re-
ferred for further testing, where ongoing symptoms are likely 
and a symptom-rhythm correlation is a feasible goal. Wide-
spread early use of the ILR is likely to result in a poor diag-
nostic yield, as an increased proportion of patients will not 
have arrhythmia, supported by data from the RAST trial 
[24,34]. The optimal patient for prolonged monitoring with 
an external or implantable loop recorder has symptoms sus-
picious for arrhythmia; namely abrupt onset with minimal 
prodrome, typically brief loss of consciousness and complete 
resolution of symptoms within seconds to minutes. ISSUE 2 
suggests that documentation of the cardioinhibitory compo-
nent of vasovagal syncope may identify a group of patients 
that respond well to pacing. Brignole and colleagues ad-
dressed this hypothesis, by evaluating the effect of placebo 
pacing therapy [36]. Syncope recurred in 38% of patients 
randomized to placebo vs. 34% randomized to no treatment. 
The recurrence rate with active cardiac pacing was 15%. The 
authors suggest that the use of specific selection criteria for 
pacing, such as characteristics of the observed cardioinhibi-
tory reflex may identify those who will respond to cardiac 
pacing [36]. 
  After clinical assessment, including assessment of left 
ventricular function, a decision must be made if the underly-
ing condition is potentially life threatening. All reports using 
the ILR have suggested a low incidence of life-threatening 
arrhythmia or significant morbidity with a prolonged moni-
toring strategy. This suggests a good prognosis for patients 
with recurrent unexplained syncope in the absence of left 
ventricular dysfunction or with negative electrophysiologic 
testing. This finding was particularly striking in the negative 
electrophysiologic testing arm of the ISSUE study (see dis-
cussion above). 
  Lastly, syncope fails to recur during long term monitor-
ing in almost one third of patients even in the presence of 
frequent episodes prior to loop recorder implantation. This 
suggests that the cause of syncope in some instances is self-
limited, reflecting a transient physiologic abnormality. Long 
term monitoring strategies may also have a role in the as-
sessment of patients who have infrequent palpitations but are 
at risk of arrhythmias. 
CONCLUSION 
  Syncope, although relatively common, remains a signifi-
cant diagnostic challenge for clinicians, despite advances in 
knowledge pertaining to mechanism. A careful history and 
examination are mandatory in the assessment of these pa-
tients,assyncope needs to be differentiated from other causes 
of loss of consciousness. The ultimate diagnostic goal is to 
correlate symptoms to rhythm disturbances, and accurate 
attainment of this goal requires the judicious use of monitor-
ing strategies. Ambulatory cardiac monitoring has provided a 
powerful means to elucidate etiology of presyncope or syn-
cope. The choice of ambulatory monitoring strategies is gov-
erned by index of suspicion of cardiac arrhythmias, fre-
quency and nature of symptoms and accuracy of the monitor-
ing device. For instance, implantable loop recorders have 
significantly improved the success of obtaining electrocar-
diographic rhythm data during spontaneous symptoms in 
patients with recurrent unexplained syncope. The clinician 
should consider early use of external and implantable loop 
recorders when an arrhythmia is suspected based on clinical 
presentation and initial non-invasive testing.  
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